{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T19:08:17Z","timestamp":1782846497877,"version":"3.54.5"},"reference-count":65,"publisher":"JMIR Publications Inc.","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMIR Diabetes"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec sec-type=\"background\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Patients with type 2 diabetes mellitus (T2D) have a higher risk of cardiovascular disease, including heart failure (HF), leading to health care burden including hospitalization and mortality. Among multiple T2D therapies, there are inadequate head-to-head comparisons of their effects on HF in the real-world patient population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec sec-type=\"objective\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aims to compare the time-to-HF among patients treated with different T2D drugs following metformin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec sec-type=\"methods\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective data analysis on electronic health records of 5000 patients with T2D. The inclusion criteria were previous treatment with metformin and initiation of glucagon-like peptide-1 receptor agonists (GLP1 RAs), dipeptidyl peptidase-4 inhibitors (DPP4i), sulfonylureas, or insulin. We grouped patients by the mechanism of their subsequent therapies and focused on 2 pairs of comparisons classified by insulin resistance: sulfonylureas versus insulin (increased resistance) and GLP1 RA versus DPP4i (decreased resistance). The outcomes were 5-year HF status and the HF-free survival time, which was verified manually by examining clinical notes. We applied doubly robust causal estimation and accounted for confounding by adjusting for coded and natural language processing electronic health record features identified through medical knowledge networks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec sec-type=\"results\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The study included 939 patients, of whom 204 (21.7%) received insulin, 482 (51.3%) received sulfonylureas, 90 (9.6%) received GLP1 RA, and 163 (17.4%) received DPP4i. Patients in the sulfonylureas group had a significantly higher 5-year HF-free survival compared to the insulin group (survival ratio of insulin\/sulfonylureas 0.902, 95% CI 0.840\u20100.976;\n                      <jats:italic>P=<\/jats:italic>\n                      .01). There was no significant difference between the DPP4i versus GLP1 RA group in 5-year HF-free survival (survival ratio of GLP1 RA\/DPP4i was 0.953, 95% CI 0.849\u20101.067;\n                      <jats:italic>P=<\/jats:italic>\n                      .40). For the occurrence of a HF-related hospitalization within 5 years, there were no significant differences between the sulfonylureas and insulin groups (risk difference 0.057, 95% CI \u20130.011 to 0.132;\n                      <jats:italic>P=<\/jats:italic>\n                      .11), and between the GLP1 RA and DPP4i groups (risk difference 0.010, 95% CI \u20130.096 to 0.129).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec sec-type=\"conclusions\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We evaluated real-world evidence on 2 head-to-head comparisons of second-line T2D therapies on 5-year HF outcomes. Patients on sulfonylureas were associated with lower 5-year HF risks than those treated with insulin when measured by risk ratio, but no significant difference was detected when measured by the risk difference. Limitations of this study included potentially inadequate adjustment of confounding in the observational study and a limited sample size with validated HF outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2196\/85083","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T18:44:05Z","timestamp":1776278645000},"page":"e85083-e85083","source":"Crossref","is-referenced-by-count":0,"title":["Antidiabetic Drug Associations With Heart Failure Outcomes: Real-World Evidence Study Using Electronic Health Records"],"prefix":"10.2196","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6093-3051","authenticated-orcid":false,"given":"Elzbieta","family":"Jodlowska-Siewert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0283-4428","authenticated-orcid":false,"given":"Yunhui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2760-6982","authenticated-orcid":false,"given":"Sinian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4595-0179","authenticated-orcid":false,"given":"Jia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8132-088X","authenticated-orcid":false,"given":"Robert","family":"Dellavalle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8258-3585","authenticated-orcid":false,"given":"Rui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9015-1827","authenticated-orcid":false,"given":"Jue","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1010","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"issue":"10397","key":"R1","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0140-6736(23)01301-6","article-title":"Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021","volume":"402","author":"GBD 2021 Diabetes Collaborators","journal-title":"Lancet"},{"key":"R2","unstructured":"National diabetes statistics report. Centers for Disease Control and Prevention; URL: https:\/\/www.cdc.gov\/diabetes\/php\/data-research\/index.html [Accessed 01-07-2025]"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2018.02.023","article-title":"IDF Diabetes Atlas: global estimates of diabetes prevalence for 2017 and projections for 2045","volume":"138","author":"Cho","journal-title":"Diabetes Res Clin Pract"},{"issue":"9529","key":"R4","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(06)68967-8","article-title":"Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study","volume":"368","author":"Booth","journal-title":"Lancet"},{"issue":"2_suppl","key":"R5","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1177\/2047487319878371","article-title":"Diabetes as a cardiovascular risk factor: an overview of global trends of macro and micro vascular complications","volume":"26","author":"Dal Canto","journal-title":"Eur J Prev Cardiol"},{"issue":"24","key":"R6","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1161\/CIRCULATIONAHA.116.022194","article-title":"Clinical update: cardiovascular disease in diabetes mellitus: atherosclerotic cardiovascular disease and heart failure in type 2 diabetes mellitus - mechanisms, management, and clinical considerations","volume":"133","author":"Low Wang","journal-title":"Circulation"},{"issue":"S3","key":"R7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/dom.15062","article-title":"Heart failure and diabetes: clinical significance and epidemiology of this two-way association","volume":"25 Suppl 3","author":"Jerkins","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"R8","doi-asserted-by":"publisher","first-page":"157","DOI":"10.18553\/jmcp.2022.28.2.157","article-title":"Burden of hospitalization for heart failure in the United States: a systematic literature review","volume":"28","author":"Osenenko","journal-title":"J Manag Care Spec Pharm"},{"issue":"1","key":"R9","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s11739-023-03458-7","article-title":"Reducing the hospitalization epidemic of chronic heart failure by disease management programs","volume":"19","author":"Belfiore","journal-title":"Intern Emerg Med"},{"key":"R10","unstructured":"Hospitalization. National Center for Health Statistics. URL: https:\/\/www.cdc.gov\/nchs\/hus\/topics\/hospitalization.htm [Accessed 01-07-2025]"},{"issue":"1","key":"R11","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-018-0746-4","article-title":"Risk of heart failure hospitalization among users of dipeptidyl peptidase-4 inhibitors compared to glucagon-like peptide-1 receptor agonists","volume":"17","author":"Dawwas","journal-title":"Cardiovasc Diabetol"},{"issue":"2","key":"R12","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/S2213-8587(18)30320-6","article-title":"Use of liraglutide and risk of major cardiovascular events: a register-based cohort study in Denmark and Sweden","volume":"7","author":"Svanstr\u00f6m","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"R13","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2020-001451","article-title":"Cardiovascular outcomes of type 2 diabetic patients treated with SGLT-2 inhibitors versus GLP-1 receptor agonists in real-life","volume":"8","author":"Longato","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"3","key":"R14","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.7420","article-title":"Reducing all-cause 30-day hospital readmissions for patients presenting with acute heart failure exacerbations: a quality improvement initiative","volume":"12","author":"Nair","journal-title":"Cureus"},{"issue":"Supplement_1","key":"R15","doi-asserted-by":"publisher","first-page":"S183","DOI":"10.2337\/dc26-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2026","volume":"49","author":"American Diabetes Association Professional Practice Committee for Diabetes","journal-title":"Diabetes Care"},{"issue":"1","key":"R16","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.33939","article-title":"Sodium-glucose cotransporter 2 (SGLT2) inhibitors: benefits versus risk","volume":"15","author":"Jasleen","journal-title":"Cureus"},{"issue":"7","key":"R17","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41569-023-00849-3","article-title":"Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action","volume":"20","author":"Ussher","journal-title":"Nat Rev Cardiol"},{"issue":"5","key":"R18","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.eprac.2023.02.001","article-title":"American Association of Clinical Endocrinology consensus statement: comprehensive type 2 diabetes management algorithm - 2023 update","volume":"29","author":"Samson","journal-title":"Endocr Pract"},{"issue":"22","key":"R19","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","journal-title":"N Engl J Med"},{"issue":"19","key":"R20","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1093\/eurheartj\/ehv728","article-title":"Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME\u00ae trial","volume":"37","author":"Fitchett","journal-title":"Eur Heart J"},{"issue":"5","key":"R21","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1161\/CIRCULATIONAHA.118.034222","article-title":"Canagliflozin and heart failure in type 2 diabetes mellitus: results from the CANVAS Program","volume":"138","author":"R\u00e5dholm","journal-title":"Circulation"},{"issue":"12","key":"R22","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","journal-title":"N Engl J Med"},{"issue":"18","key":"R23","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1161\/CIRCULATIONAHA.114.010389","article-title":"Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial","volume":"130","author":"Scirica","journal-title":"Circulation"},{"issue":"12","key":"R24","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1161\/CIRCULATIONAHA.120.045888","article-title":"Glucagon-like peptide 1 receptor agonists and heart failure: the need for further evidence generation and practice guidelines optimization","volume":"142","author":"Khan","journal-title":"Circulation"},{"issue":"6","key":"R25","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1002\/pds.5222","article-title":"Real\u2010world evidence to support regulatory decision making: new or expanded medical product indications","volume":"30","author":"Franklin","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R26","doi-asserted-by":"publisher","DOI":"10.2196\/45662","article-title":"Generate analysis-ready data for real-world evidence: tutorial for harnessing electronic health records with advanced informatic technologies","volume":"25","author":"Hou","journal-title":"J Med Internet Res"},{"issue":"9","key":"R27","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/S2213-8587(23)00171-7","article-title":"Comparative effectiveness of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of major adverse cardiovascular events: emulation of a randomised target trial using electronic health records","volume":"11","author":"Xie","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R28","doi-asserted-by":"publisher","DOI":"10.2196\/58137","article-title":"Comparing insulin against glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase-4 inhibitors, and sodium-glucose cotransporter 2 inhibitors on 5-year incident heart failure risk for patients with type 2 diabetes mellitus: real-world evidence study using insurance claims","volume":"9","author":"Wang","journal-title":"JMIR Diabetes"},{"issue":"1","key":"R29","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/nyas.12044","article-title":"Cardiovascular disease and glycemic control in type 2 diabetes: now that the dust is settling from large clinical trials","volume":"1281","author":"Giorgino","journal-title":"Ann N Y Acad Sci"},{"issue":"3","key":"R30","doi-asserted-by":"publisher","first-page":"100444","DOI":"10.1016\/j.hjdsi.2020.100444","article-title":"How much can we trust electronic health record data?","volume":"8","author":"Savitz","journal-title":"Healthc (Amst)"},{"issue":"1","key":"R31","doi-asserted-by":"publisher","DOI":"10.1038\/s41746-021-00519-z","article-title":"Clinical knowledge extraction via sparse embedding regression (KESER) with multi-center large scale electronic health record data","volume":"4","author":"Hong","journal-title":"NPJ Digit Med"},{"key":"R32","doi-asserted-by":"crossref","unstructured":"Xiong X Sweet SM Liu M et al. Knowledge-driven online multimodal automated phenotyping system. medRxiv. Mar 5, 2025:2023.09.29.23296239. [doi: 10.1101\/2023.09.29.23296239] [Medline: 37873131]","DOI":"10.1101\/2023.09.29.23296239"},{"key":"R33","volume":"2017","author":"Horsky","journal-title":"AMIA Annu Symp Proc"},{"key":"R34","volume":"2019","author":"Weiskopf","journal-title":"AMIA Annu Symp Proc"},{"issue":"12","key":"R35","doi-asserted-by":"publisher","first-page":"3426","DOI":"10.1038\/s41596-019-0227-6","article-title":"High-throughput phenotyping with electronic medical record data using a common semi-supervised approach (PheCAP)","volume":"14","author":"Zhang","journal-title":"Nat Protoc"},{"issue":"5","key":"R36","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1002\/acr.24804","article-title":"Association between inflammation, incident heart failure, and heart failure subtypes in patients with rheumatoid arthritis","volume":"75","author":"Huang","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"R37","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1542\/hpeds.2019-0225","article-title":"Structured chart review: assessment of a structured chart review methodology","volume":"10","author":"Siems","journal-title":"Hosp Pediatr"},{"issue":"1","key":"R38","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-022-00850-9","article-title":"Dipeptidyl peptidase 4 inhibitor improves insulin resistance in Japanese patients with type 2 diabetes: a single-arm study, a brief report","volume":"14","author":"Okura","journal-title":"Diabetol Metab Syndr"},{"issue":"4","key":"R39","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1111\/j.1541-0420.2005.00377.x","article-title":"Doubly robust estimation in missing data and causal inference models","volume":"61","author":"Bang","journal-title":"Biometrics"},{"issue":"541","key":"R40","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1080\/01621459.2021.1930546","article-title":"Treatment effect estimation under additive hazards models with high-dimensional confounding","volume":"118","author":"Hou","journal-title":"J Am Stat Assoc"},{"issue":"9","key":"R41","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1093\/bioinformatics\/btq126","article-title":"PheWAS: demonstrating the feasibility of a phenome-wide scan to discover gene-disease associations","volume":"26","author":"Denny","journal-title":"Bioinformatics"},{"issue":"11","key":"R42","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1093\/jamia\/ocz066","article-title":"High-throughput multimodal automated phenotyping (MAP) with application to PheWAS","volume":"26","author":"Liao","journal-title":"J Am Med Inform Assoc"},{"key":"R43","volume":"24","author":"Hou","journal-title":"J Mach Learn Res"},{"key":"R44","unstructured":"Yu S Cai T Cai T . NILE: fast natural language processing for electronic health records. arXiv. Preprint posted online on Nov 23, 2013. [doi: 10.48550\/arXiv.1311.6063]"},{"issue":"Database issue","key":"R45","doi-asserted-by":"publisher","first-page":"D267","DOI":"10.1093\/nar\/gkh061","article-title":"The Unified Medical Language System (UMLS): integrating biomedical terminology","volume":"32","author":"Bodenreider","journal-title":"Nucleic Acids Res"},{"issue":"2","key":"R46","doi-asserted-by":"publisher","first-page":"135","DOI":"10.5114\/aic.2021.107491","article-title":"Dapagliflozin in the treatment of patients with heart failure with reduced left ventricular ejection fraction \u2013 a practical approach","volume":"17","author":"Nessler","journal-title":"Postepy Kardiol Interwencyjnej"},{"issue":"5","key":"R47","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.019463","article-title":"Effects of sodium\/glucose cotransporter 2 (SGLT2) inhibitors on cardiovascular and metabolic outcomes in patients without diabetes mellitus: a systematic review and meta-analysis of randomized-controlled trials","volume":"10","author":"Teo","journal-title":"J Am Heart Assoc"},{"issue":"6","key":"R48","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.cardfail.2008.02.007","article-title":"Pioglitazone and heart failure: results from a controlled study in patients with type 2 diabetes mellitus and systolic dysfunction","volume":"14","author":"Giles","journal-title":"J Card Fail"},{"issue":"4","key":"R49","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1136\/amiajnl-2011-000116","article-title":"Normalized names for clinical drugs: RxNorm at 6 years","volume":"18","author":"Nelson","journal-title":"J Am Med Inform Assoc"},{"key":"R50","volume":"26","author":"Hou","journal-title":"J Mach Learn Res"},{"issue":"3","key":"R51","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1136\/jamia.1998.0050276","article-title":"Development of the Logical Observation Identifier Names and Codes (LOINC) vocabulary","volume":"5","author":"Huff","journal-title":"J Am Med Inform Assoc"},{"key":"R52","unstructured":"Clinical Classifications Software for Services and Procedures. US Agency for Healthcare Research and Quality. 2014. URL: https:\/\/hcup-us.ahrq.gov\/toolssoftware\/ccs_svcsproc\/ccssvcproc.jsp [Accessed 01-07-2025]"},{"issue":"427","key":"R53","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1080\/01621459.1994.10476818","article-title":"Estimation of regression coefficients when some regressors are not always observed","volume":"89","author":"Robins","journal-title":"J Am Stat Assoc"},{"issue":"476","key":"R54","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1198\/016214506000000735","article-title":"The adaptive lasso and its oracle properties","volume":"101","author":"Zou","journal-title":"J Am Stat Assoc"},{"key":"R55","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S312997","article-title":"Metformin-insulin versus metformin-sulfonylurea combination therapies in type 2 diabetes: a comparative study of glycemic control and risk of cardiovascular diseases in Addis Ababa, Ethiopia","volume":"14","author":"Gebrie","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"8","key":"R56","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2018.6125","article-title":"Association of second-line antidiabetic medications with cardiovascular events among insured adults with type 2 diabetes","volume":"1","author":"O\u2019Brien","journal-title":"JAMA Netw Open"},{"issue":"5","key":"R57","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.pcd.2021.04.005","article-title":"Heart failure outcomes and glucagon-like peptide-1 receptor agonists: a systematic review of observational studies","volume":"15","author":"Alkhezi","journal-title":"Prim Care Diabetes"},{"issue":"1","key":"R58","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.pcd.2021.11.006","article-title":"Cardiovascular effectiveness of glucagon-like peptide 1 receptor agonists versus dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a meta-analysis based on propensity score-matched studies","volume":"16","author":"Xu","journal-title":"Prim Care Diabetes"},{"issue":"11","key":"R59","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1002\/ejhf.1594","article-title":"Survival of patients with chronic heart failure in the community: a systematic review and meta-analysis","volume":"21","author":"Jones","journal-title":"Eur J Heart Fail"},{"issue":"5","key":"R60","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.jacc.2023.05.040","article-title":"Global comparison of readmission rates for patients with heart failure","volume":"82","author":"Foroutan","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"R61","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1016\/j.jacc.2009.08.019","article-title":"Hospitalizations after heart failure diagnosis a community perspective","volume":"54","author":"Dunlay","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"R62","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1002\/ejhf.1494","article-title":"Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations","volume":"21","author":"Mueller","journal-title":"Eur J Heart Fail"},{"issue":"14","key":"R63","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1056\/NEJMsm1605385","article-title":"Per-protocol analyses of pragmatic trials","volume":"377","author":"Hern\u00e1n","journal-title":"N Engl J Med"},{"issue":"1","key":"R64","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S2213-8587(19)30384-5","article-title":"Kidney outcomes associated with use of SGLT2 inhibitors in REAL-world clinical practice (CVD-REAL 3): a multinational observational cohort study","volume":"8","author":"Heerspink","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"R65","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-057977","article-title":"Large-scale evidence generation and evaluation across a network of databases for type 2 diabetes mellitus (LEGEND-T2DM): a protocol for a series of multinational, real-world comparative cardiovascular effectiveness and safety studies","volume":"12","author":"Khera","journal-title":"BMJ Open"}],"container-title":["JMIR Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetes.jmir.org\/2026\/1\/e85083","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T18:19:10Z","timestamp":1782843550000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetes.jmir.org\/2026\/1\/e85083"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":65,"URL":"https:\/\/doi.org\/10.2196\/85083","relation":{},"ISSN":["2371-4379"],"issn-type":[{"value":"2371-4379","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,15]]},"article-number":"v11i10397e85083"}}